Literature DB >> 20212271

Impact of blood pressure lowering on cardiovascular outcomes in normal weight, overweight, and obese individuals: the Perindopril Protection Against Recurrent Stroke Study trial.

Sébastien Czernichow1, Toshiharu Ninomiya, Rachel Huxley, André-Pascal Kengne, G David Batty, Diederick E Grobbee, Mark Woodward, Bruce Neal, John Chalmers.   

Abstract

There is considerable uncertainty regarding the efficacy of blood pressure-lowering therapy in reducing cardiovascular risk in obese people. In this report we examine the effects of blood pressure lowering according to baseline body mass index (kilograms per meter squared) in the Perindopril Protection Against Recurrent Stroke Study. A total of 6105 participants with cerebrovascular disease were randomized to perindopril-based blood pressure-lowering therapy or placebo. The overall mean difference in systolic/diastolic blood pressure between participants assigned active therapy or placebo was 9/4 mm Hg (SE: 0.5/0.3 mm Hg), with no difference by body mass index quarters (<23.1, 23.1 to 25.3, 25.4 to 27.8, and > or = 27.9 kg/m(2)). A consistent treatment benefit was demonstrated for protection against major vascular events across quarters with the following hazard ratios (95% CIs): 0.80 (0.62 to 1.02), 0.78 (0.61 to 1.01), 0.67 (0.53 to 0.86), 0.69 (0.54 to 0.88), and 0.74 (0.66 to 0.84; P for heterogeneity=0.16). Similar results were apparent for stroke and stroke subtypes (all P for heterogeneity > or = 0.07) or with the standard definitions of overweight and obesity (<25, 25 to 29, and > or = 30 kg/m(2); all P for heterogeneity > or = 0.28). The absolute effects of treatment were, however, more than twice that in the highest compared with the lowest body mass index quartile. Across increasing quarters of body mass index over 5 years, active therapy prevented 1 major vascular event among every 28, 23, 13, and 13 patients treated. In conclusion, blood pressure-lowering therapy produced comparable risk reductions in vascular disease across the whole range of body mass indices in participants with a history of stroke. However, the greater baseline level of cardiovascular risk in those with higher body mass index meant that these patients obtained the greatest benefit.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20212271      PMCID: PMC4170774          DOI: 10.1161/HYPERTENSIONAHA.109.140624

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  32 in total

Review 1.  Obesity.

Authors:  David W Haslam; W Philip T James
Journal:  Lancet       Date:  2005-10-01       Impact factor: 79.321

Review 2.  Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review.

Authors:  Lorna Aucott; Amudha Poobalan; W Cairns S Smith; Alison Avenell; Roland Jung; John Broom
Journal:  Hypertension       Date:  2005-05-16       Impact factor: 10.190

Review 3.  European Society of Hypertension Working Group on Obesity: background, aims and perspectives.

Authors:  Jens Jordan; Stefan Engeli; Josep Redon; Arya M Sharma; Friedrich C Luft; Krzysztof Narkiewicz; Guido Grassi
Journal:  J Hypertens       Date:  2007-04       Impact factor: 4.844

4.  Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.

Authors:  Lars Sjöström; Anna-Karin Lindroos; Markku Peltonen; Jarl Torgerson; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Bo Larsson; Kristina Narbro; Carl David Sjöström; Marianne Sullivan; Hans Wedel
Journal:  N Engl J Med       Date:  2004-12-23       Impact factor: 91.245

Review 5.  Diagnosis and management of hypertension in obesity.

Authors:  K Narkiewicz
Journal:  Obes Rev       Date:  2006-05       Impact factor: 9.213

6.  PROGRESS (perindopril protection against recurrent stroke study): rationale and design. PROGRESS Management Committee [corrected].

Authors:  B Neal; S MacMahon
Journal:  J Hypertens       Date:  1995-12       Impact factor: 4.844

7.  Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group.

Authors:  E Reisin; M R Weir; B Falkner; H G Hutchinson; D A Anzalone; M L Tuck
Journal:  Hypertension       Date:  1997-07       Impact factor: 10.190

8.  Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.

Authors:  Jürgen Scholze; Elmar Grimm; Dana Herrmann; Thomas Unger; Ulrich Kintscher
Journal:  Circulation       Date:  2007-04-02       Impact factor: 29.690

9.  Prevalence of overweight and obesity in the United States, 1999-2004.

Authors:  Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal
Journal:  JAMA       Date:  2006-04-05       Impact factor: 56.272

10.  Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients.

Authors:  Jens Jordan; Stefan Engeli; Michael Boschmann; Gottfried Weidinger; Friedrich C Luft; Arya M Sharma; Ursula Kreuzberg
Journal:  J Hypertens       Date:  2005-12       Impact factor: 4.844

View more
  4 in total

Review 1.  Heart disease and stroke statistics--2013 update: a report from the American Heart Association.

Authors:  Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; David Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Graham Nichol; Nina P Paynter; Pamela J Schreiner; Paul D Sorlie; Joel Stein; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2012-12-12       Impact factor: 29.690

2.  Should Blood Pressure Targets After Lacunar Stroke Vary by Body Size? The SPS3 Trial.

Authors:  Thalia S Field; Leslie A McClure; Carole L White; Pablo E Pergola; Robert G Hart; Oscar R Benavente; Michael D Hill
Journal:  Am J Hypertens       Date:  2014-12-01       Impact factor: 2.689

Review 3.  PROGRESS: Prevention of Recurrent Stroke.

Authors:  Hisatomi Arima; John Chalmers
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-09-02       Impact factor: 3.738

4.  Beneficial Effects of a Perindopril/Indapamide Single-Pill Combination in Hypertensive Patients with Diabetes and/or Obesity or Metabolic Syndrome: A Post Hoc Pooled Analysis of Four Observational Studies.

Authors:  Csaba Farsang; Csaba Andras Dézsi; Romualda Brzozowska-Villatte; Martine De Champvallins; Maria Glezer; Yuri Karpov
Journal:  Adv Ther       Date:  2021-02-25       Impact factor: 3.845

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.